21st.BIO was founded with one simple mission: to make leading industrial scale precision fermentation technology accessible to as many as possible, so companies can successfully take biotech innovations to market at a competitive price. 21st.BIO focuses on developing industrial production technology for proteins and other molecules of interest for food, nutrition, agriculture, biomaterials, and biomining industries. 21st.BIO's founders saw that too often, great bio innovation and molecules fail to translate into commercial success. The innovation is ready, the market is there, but production costs remain too high for the product to go mainstream. Industry insiders call it the 'valley of death', and that's exactly what 21st.BIO intends to bridge. Founded in 2020, 21st.BIO is headquartered in Copenhagen, Denmark, and has a world-class R&D team as well as laboratories in both Copenhagen, Denmark and Davis, California. On a mission to support bio industrial companies globally in upscaling from molecule innovation to large-scale production, 21st.BIO enables its customers to meet market demands, and thereby advance the green transition globally. Established as a fully integrated end-to-end partner, 21st.BIO supports its customers from technical assessment, strain development and optimization, production processes and upscaling, tech transfer to large scale manufacturing and regulatory services. 21st.BIO's fermentation technology is in part licensed from Novonesis, who have developed and perfected their platform over several decades.
| Website | http://www.21st.bio |
| Revenue | $11 million |
| Employees | 66 (51 on RocketReach) |
| Phone | +1 614-777-1000 |
| Industry | Biotechnology Research |
| Keywords | Bioreactor Technology, Precision Fermentation, Process Optimization, Industrial Biotechnology, Biomanufacturing, Contract Manufacturing, Fermentation Technology, Biotech Innovation, Bioprocessing, Microbial Fermentation, Industrial Enzymes, Sustainable Biomanufacturing, Green Biotechnology, Advanced Fermentation, Cell Culture Technology, Protein Production, Upstream Processing, Downstream Processing |
| Competitors | Illumina, Ancestry, GeneDx, Ambry Genetics, Invitae, MyHeritage, Fulgent Genetics, 23andMe, Gene by Gene, Color +32 more (view full list) |
Looking for a particular 21st.BIO employee's phone or email?
The 21st.BIO annual revenue was $11 million in 2026.
Thomas Schmidt is the Founder and CEO of 21st.BIO.
51 people are employed at 21st.BIO.